Detalhe da pesquisa
1.
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Hepatology
; 79(5): 1098-1106, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862551
2.
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.
Clin Gastroenterol Hepatol
; 22(1): 81-90.e4, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406954
3.
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
J Hepatol
; 78(3): 471-478, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410554
4.
Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
Hepatology
; 71(3): 849-860, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31556124
5.
Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes.
Aliment Pharmacol Ther
; 58(6): 585-592, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37431679
6.
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.
Aliment Pharmacol Ther
; 55(7): 820-827, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229334
7.
Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.
J Clin Invest
; 132(21)2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36317632
8.
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
Aliment Pharmacol Ther
; 53(9): 1030-1037, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764550